| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
723.09(B) |
| Last
Volume: |
3,201,799 |
Avg
Vol: |
3,289,637 |
| 52
Week Range: |
$390.35 - $792.28 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
435,750 |
871,420 |
2,951,506 |
6,211,418 |
| Total Sell Value |
$330,574,311 |
$608,633,217 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
2 |
2 |
5 |
6 |
| Total Sell Transactions |
5 |
14 |
46 |
89 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  White Anne E. |
EVP & Pres, Lilly Neuroscience |
• – – |
2023-02-10 |
4 |
AS |
$342.76 |
$856,900 |
D/D |
(2,500) |
60,426 |
|
33% |
|
| White Anne E. |
EVP & Pres, Lilly Neuroscience |
• – – |
2023-02-10 |
4 |
A |
$345.12 |
$2,954,917 |
D/D |
8,562 |
62,926 |
|
- |
|
| Weems Alonzo |
EVP, ERM & CECO |
• – – |
2023-02-10 |
4 |
A |
$345.12 |
$835,881 |
D/D |
2,422 |
8,922 |
|
- |
|
| Yuffa Ilya |
EVP & President, LLY Intl |
• – – |
2023-02-10 |
4 |
A |
$345.12 |
$465,912 |
D/D |
1,350 |
12,974 |
|
- |
|
| Mason Michael B |
EVP & Pres., Lilly Diabetes |
• – – |
2023-02-10 |
4 |
A |
$345.12 |
$2,768,898 |
D/D |
8,023 |
39,284 |
|
- |
|
| Zakrowski Donald A |
SVP, Finance, & CAO |
• – – |
2023-02-10 |
4 |
A |
$345.12 |
$657,108 |
D/D |
1,904 |
7,178 |
|
- |
|
| Norton Johna |
EVP, Global Quality |
• – – |
2023-02-10 |
4 |
A |
$345.12 |
$865,216 |
D/D |
2,507 |
33,908 |
|
- |
|
| Ricks David A |
President, Chair, and CEO |
• • – |
2023-02-10 |
4 |
A |
$345.12 |
$19,398,505 |
D/D |
56,208 |
443,751 |
|
- |
|
| Jonsson Patrik |
EVP&Pres, LLY Imm, LLY USA&CCO |
• – – |
2023-02-10 |
4 |
A |
$345.12 |
$2,721,616 |
D/D |
7,886 |
42,941 |
|
- |
|
| Ashkenazi Anat |
EVP & CFO |
• – – |
2023-02-10 |
4 |
A |
$345.12 |
$2,309,888 |
D/D |
6,693 |
38,120 |
|
- |
|
| Van Naarden Jacob |
EVP and CEO Loxo@Lilly |
• – – |
2023-02-10 |
4 |
A |
$345.12 |
$830,704 |
D/D |
2,407 |
10,374 |
|
- |
|
| Hernandez Edgardo |
EVP & Pres., Mfg. Operations |
• – – |
2023-02-10 |
4 |
A |
$345.12 |
$1,796,004 |
D/D |
5,204 |
25,814 |
|
- |
|
| Ricks David A |
President, Chair, and CEO |
• • – |
2023-02-08 |
4 |
GD |
$0.00 |
$0 |
D/D |
4,200 |
387,543 |
|
- |
|
| Norton Johna |
EVP, Global Quality |
• – – |
2023-02-01 |
4 |
D |
$344.15 |
$323,845 |
D/D |
(941) |
31,401 |
|
- |
|
| Norton Johna |
EVP, Global Quality |
• – – |
2023-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,102 |
32,342 |
|
- |
|
| Jonsson Patrik |
EVP&Pres, LLY Imm, LLY USA&CCO |
• – – |
2023-02-01 |
4 |
D |
$344.15 |
$1,031,418 |
D/D |
(2,997) |
35,055 |
|
- |
|
| Jonsson Patrik |
EVP&Pres, LLY Imm, LLY USA&CCO |
• – – |
2023-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,690 |
38,052 |
|
- |
|
| Skovronsky Daniel |
EVP, CS&MO & Pres., LRL |
• – – |
2023-02-01 |
4 |
D |
$344.15 |
$2,421,095 |
D/D |
(7,035) |
87,199 |
|
- |
|
| Skovronsky Daniel |
EVP, CS&MO & Pres., LRL |
• – – |
2023-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,675 |
94,234 |
|
- |
|
| Pusey Leigh Ann |
EVP, Corp. Affairs & Comm. |
• – – |
2023-02-01 |
4 |
D |
$344.15 |
$494,888 |
D/D |
(1,438) |
27,960 |
|
- |
|
| Pusey Leigh Ann |
EVP, Corp. Affairs & Comm. |
• – – |
2023-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,154 |
29,398 |
|
- |
|
| Hakim Anat |
EVP, GC & Secretary |
• – – |
2023-02-01 |
4 |
D |
$344.15 |
$1,167,701 |
D/D |
(3,393) |
13,117 |
|
- |
|
| Hakim Anat |
EVP, GC & Secretary |
• – – |
2023-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,646 |
16,510 |
|
- |
|
| Mason Michael B |
EVP & Pres., Lilly Diabetes |
• – – |
2023-02-01 |
4 |
D |
$344.15 |
$1,010,080 |
D/D |
(2,935) |
31,261 |
|
- |
|
| Mason Michael B |
EVP & Pres., Lilly Diabetes |
• – – |
2023-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,690 |
34,196 |
|
- |
|
3297 Records found
|
|
Page 9 of 132 |
|
|
20.84 (2.68%) 
